Lung Transplant Extends Survival for Terminal Lung Cancer Patients

A groundbreaking study led by Northwestern Medicine, published in the *Journal of the American Medical Association* (JAMA), reveals that lung transplantation can significantly prolong survival for a subset of patients with advanced lung cancer who are ineligible for other treatments. The research challenges conventional approaches by demonstrating that selected patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) may benefit from lung transplants, offering a potential paradigm shift in oncology care.

The study analyzed outcomes of 55 patients who underwent lung transplants at Northwestern Memorial Hospital between 2000 and 2022, comparing them to a historical cohort of 110 NSCLC patients who received standard therapies. Transplant recipients showed a median survival of 68 months, compared to 28 months for those treated with conventional methods. Patients selected for transplants had no distant metastases, tumors confined to the lung, and no prior chemotherapy. Notably, 30% of transplant recipients survived beyond five years, a stark improvement over the typical prognosis for advanced NSCLC. Researchers emphasized that the procedure is not a universal solution but could be a viable option for a carefully screened cohort.

While the findings suggest lung transplantation could become a new standard for specific advanced lung cancer cases, experts caution that the approach requires further validation through larger trials. Northwestern’s team, led by Dr. Joseph Friedberg, highlighted the need for multidisciplinary evaluation to identify suitable candidates, given the risks of transplant surgery and limited donor availability. The study underscores the potential for innovative, life-extending strategies in oncology, though broader implementation will depend on confirming long-term efficacy and addressing logistical challenges.